20. Paule B, Bastien L, Deslandes E et al. Background: Variations in urothelial carcinoma (UC) response to platinum chemotherapy are common and frequently attributed to genetic and epigenetic variations of somatic DNA. We hypothesized that variations in germline DNA may contribute to UC chemosensitivity.
introduction
Neoadjuvant cisplatin-based chemotherapy is the standard of care for the treatment of muscle-invasive urothelial carcinoma (UC) [1] [2] [3] , while both cisplatin-and carboplatin-based therapy have efficacy in patients with metastatic disease [4, 5] . Unfortunately, despite being considered a chemotherapysensitive disease, only 32%-38% of patients with muscleinvasive disease and 40%-50% of patients with metastatic disease have a major response to platinum-based chemotherapy [1, 2, 4, 5] . Other than clinical stage of the primary tumor, pretreatment factors predictive of response in the neoadjuvant setting are lacking. In contrast, Karnofsky performance status (KPS) <80% and the presence of visceral (lung, liver, or bone) metastases have been used in the MSKCC clinical risk score [5, 6] , which correlates with both response and survival in the † The study was presented as an oral presentation at the American Society of Clinical Oncology Annual Meeting and Genitourinary Cancers Symposium in 2011.
metastatic disease setting [6, 7] . However, even this clinicalbased model is substantially limited in clinical practice; it is predominantly used for clinical trial stratification to balance for prognostic factors that may impact trial results.
There is an urgent need to identify individuals most likely to respond to platinum-based chemotherapy and to avoid this treatment and its associated toxic effect in the >50% patients unlikely to respond. This is particularly important in the neoadjuvant setting where major response is seen in approximately one-third of patients and a delay of surgical resection may have profound effects on survival. Although response to chemotherapy may be a function of both tumor and host characteristics, the majority of research to date has focused on tumor characteristics. Some prognostic and predictive tumor-based UC biomarkers, such as p53, mdm-2, and bcl-2, have been identified [8] [9] [10] [11] [12] [13] . Tumor-based markers associated with repair of platinum-induced DNA damage have also been identified; low ERCC1 messenger RNA expression levels have been associated with improved survival [14] and low BRCA1 messenger RNA expression levels are associated with response to neoadjuvant cisplatin-based chemotherapy [15] . While these markers have shown promise, their results have not been externally or prospectively validated.
Germline genetic variation is an excellent candidate for research in characterizing the role of the host in predicting response to chemotherapy because it is constitutional, stable over time, and easily measured in the clinical setting. Germline variation has an advantage over somatic variation whose translation into the clinical setting is complicated by a number of characteristics, including tissue heterogeneity and evolution of molecular changes, which may result in variable molecular profiles within the same tumor or at different stages of tumor development.
To date, no study has examined germline genetic variation as a potential marker of response to systemic therapy for UC. In this biomarker discovery study, we identified 80 SNPs from the literature that have been reported to be associated with the risk of developing UC or response and/or toxic effect to platinum chemotherapy in any cancer, and investigated the ability of these candidate SNPs to predict response of UC to platinumbased chemotherapy in both the neo-adjuvant and metastatic disease settings.
materials and methods
Between May 2009 and June 2010, saliva or blood samples were prospectively collected from 651 patients who were diagnosed with UC. All patients gave written consent to an IRB-approved protocol and completed an epidemiology questionnaire. Of these patients, 328 had advanced disease and received platinum-based chemotherapy either at MSKCC or a referring center; 210 of these patients were assessable (had both sufficient genotyping and response data available) for our analysis. Clinical data were ascertained on all patients and included age, stage, treatment type (carboplatin or cisplatin), treatment setting (neoadjuvant or metastatic), response, and MSKCC clinical risk score. The two clinical variables included in the MSKCC clinical risk score were KPS <80% and the presence of visceral metastases; all patients were scored in the model as 0 (neither risk factor), 1 (either), or 2 (both factors). Response in metastatic disease patients was assessed clinically by the treating physician (without post-treatment biopsies) and documented categorically as either response (complete or partial response (CR, PR)) or no response (including progression of disease); radiographic assessments and RECIST measurements were not centrally reviewed. In the neoadjuvant setting, CR was defined as no evidence of residual carcinoma in the postchemotherapy surgical specimen and a PR was defined as no residual muscle invasive cancer (i.e., <pT2 stage). Response was determined from pathology reports; independent pathologic review of the postchemotherapy specimens was not carried out.
All saliva and blood samples were genotyped for the 80 SNPs using a Mass ARRAY iPLEX system (Sequenom, Inc., San Diego, CA). All patient samples were anonymized for analysis and investigators performing the genotyping were blinded to the clinical information. The SNPs were selected for study based on their previously published association with UC diagnosis, platinum response, or platinum toxic effect in genome-wide association studies or candidate gene studies, or were SNPs of particular interest to our group (arising from internal results in other experiments). The primers were ordered from Sequenom, Inc.. All SNPS met our established quality assurance filters which included a call rate ≥95% and a minor allele frequency ≥1%. Only one SNP was not in Hardy-Weinberg equilibrium at P < 0.00001, consistent with our expectation in this case-only analysis.
cell line validation
We sought to validate the SNP score in 11 bladder cancer cell lines that were characterized for cisplatin sensitivity using half maximal inhibitory concentration (IC50) measurements. Each cell line was grown in appropriate media at 37°C and harvested at 50%-80% confluence. Cells were plated in 96-well dishes at a density ranging from 2500 to 5000 cells/well depending on cell size, and cisplatin was added at increasing concentrations from 0.5 to 50 μM. The cells were then incubated for 48 h before the addition of AlamarBlue cell viability reagent (Invitrogen, Inc.). Fluorescence intensity was measured after 4 h of exposure to the reagent and correlated with cell number, and an IC50 value was calculated based upon the corresponding cisplatin concentration. At least four replicate IC50 values were generated for each cell line. Genotyping was carried out on the cell lines for the SNPs included in the SNP score using the same Mass ARRAY QGE iPLEX system (Sequenom, Inc.). For one cell line, SW1710, it was not possible to define SNP status using mass spectrometric genotyping so select SNP genotypes for this cell line were defined by Sanger sequencing.
statistical analysis
Association between response and clinical variables was tested using the Fisher's exact test for categorical predictors and the Wilcoxon rank sum test for continuous predictors. Logistic regression was used to investigate the association between each SNP and platinum response. Each SNP was analyzed using a log-additive (one degree of freedom) model and a codominant model, in which case, the association was determined from a global test for differences in outcome between the three genotypes (common homozygote, heterozygote, and rare homozygote), commonly referred to as a '2 degree of freedom test.' As this study was intended to be hypothesis generating, the results were not adjusted for multiple testing; statistical significance was defined as P < 0.05. SNPs retaining independent association with response after adjusting for clinical covariates were combined into a predictive model to generate a SNP score predictive of platinum response. Each significant SNP contributed 0, 1, or 2 risk alleles for each patient. A risk allele was defined as the allele associated with lack of response to platinum. Thus, a lower SNP score corresponds to a greater likelihood of responding to platinum.
Finally, the discriminating ability of predictive models was compared by plots of receiver-operating characteristic (ROC) curves and area under the curves (AUC). AUC values were bootstrap-adjusted (1000 samples) to 
patient population
The median age of the 210 patients with UC patients was 65 years (range 31-85 years) and the majority (72%) of patients were male (Table 1) . Eighty-four percent of patients had a bladder primary. Sixty-seven percent of patients received chemotherapy in the metastatic or advanced disease setting. All neoadjuvant systemic treatment was cisplatin based.
treatment response
Seventy patients received neoadjuvant treatment and 140 patients received chemotherapy for metastatic or advanced disease. In the advanced/metastatic setting, 135 were chemotherapy-naïve before first-line metastatic treatment, and five received treatment of metastatic disease relapse after prior chemoradiotherapy for muscle-invasive disease. Five patients classified as receiving first-line systemic treatment of metastatic disease had prior adjuvant chemotherapy. There were 67 of 129 (52%) patients who responded to cisplatin therapy and 31 of 81 (38%) who responded to carboplatin therapy; observed response rates in this series are consistent with published data for both cisplatin-and carboplatin-based treatment. Five patients were treated with carboplatin after prior perioperative treatment of muscle-invasive disease with one response. All other patients were chemonaive. Only MSKCC risk score, site of metastasis, and treatment were significantly associated with chemotherapy response.
individual SNP analysis
A univariate analysis of all available patients identified seven SNPs that were significantly associated with platinum response by the one degree of freedom test, the two degree of freedom test, or both (Table 2 ). For each of the 80 SNPs, the genotypes were missing in a median of 1.5 of 210 patients. A subset analysis of the 70 patients who received neoadjuvant chemotherapy identified a different set of five SNPs significantly associated with platinum response. Only two SNPs were common to both lists (rs6512670 and rs1520896) (data not shown). Five SNPs remained significantly associated with response by either per allele or two degree of freedom test after adjusting for the MSKCC clinical risk score ( Table 2 ). The multivariable model did not control for treatment type because it was no longer significant after the risk score was included. One of the remaining significant SNPs, rs1143627, was excluded from the SNP score model as it was in linkage disequilibrium with rs16944. The remaining four significant SNPs were included in the multivariable model.
multiple SNP analysis
The four SNPs were combined into a predictive model that generated a SNP score ranging between 0 and 8, which increases as the proportion of responses decreases (Figure 1 ). The SNP score was calculated as the number of at-risk alleles: the sum of the number of C alleles in rs6512670, number of T alleles in rs1520896, number of G alleles in rs16944, and value 2 if rs9344 had the AA genotype and 0 otherwise. Five patients with incomplete genotyping data were excluded from analysis. In a multivariable model that included the MSKCC clinical risk score, each additional at-risk allele of the SNP score was associated with a nearly 50% decrease in odds of response [OR = 0. 51, 95% confidence interval (CI) 0.39-0.65, P = 1.05 × 10
−7 ]. The bootstrap-adjusted AUC of this model was 0.78 (Figure 2 ), a marked improvement over 0.64 seen with the MSKCC clinical score alone. A bootstrap adjustment was carried out to account for the fact that the model was generated and tested on the same patient cohort. 
cell line data
The IC50 values for the 11 cell lines included in this analysis ranged from 1.548 to 12.3 µM. Three cell lines with very high variability between replicates (standard deviations >1.69) were excluded from the analysis based on lack of reproducibility ( Table 3) . The remaining eight cell lines included in the analysis were observed to have standard deviations <0.88 and considered reproducibly informative. IC50 values for each cell line were averaged across replicates and showed a positive trend with the SNP score; however, this trend did not achieve significance (Kendall's correlation coefficient 0.48, P = 0.115, Figure 3 ).
discussion
We identified four germline SNPs that were significantly associated with response of UC to platinum-based chemotherapy, and report a SNP model that predicts likelihood of response. Linkage studies using lymphoblastoid cell lines from pedigrees of Caucasian individuals have indicated that ∼47% of the variation in susceptibility to cisplatin-induced cytotoxicity is because of heritable factors [16] . Germline variants have shown to be promising predictors of toxic effect and/or response to therapy in other malignancies such as response of renal cell carcinoma to sunitinib and pazopanib [17, 18] , disease-free, and overall survival (OS) of prostate cancer treated with androgen deprivation therapy [19] , response of breast cancer to tamoxifen [20] , and toxic effect of irinotecan in the treatment of colon cancer [21] . Similarly, an improved understanding of the association between the four independent loci identified in this study, and platinum sensitivity may develop our understanding of platinum response and reveal potentially novel therapeutic strategies for UC. To the best of our knowledge, the four significant loci reported here have not been previously associated with response of UC to platinum-based chemotherapy. However, all the loci are biologically plausible mediators of platinum response. IL1B is a proinflammatory cytokine that regulates the expression of genes involved in inflammation. It appears to determine a patient's inflammatory response to Helicobacter pylori in the etiology of gastric cancer, and has been associated with OS in gastric cancer [22] , wherein platinum is a mainstay treatment of advanced disease. CCND1 is a key protein in regulation of cell cycle at the G1-to-S transition phase. It has been associated with the risk of UC [23] , migration and invasion of breast cancer [24] , and UC cell invasion [25] , and is associated with shortened OS in muscle-invasive UC [26] . Interestingly, our group and others have observed frequent somatic mutations of CCND1 and other cell-cycle regulatory genes in primary bladder cancers [27] . Overexpression of PARD6B negatively regulates the formation of tight junctions at epithelial cell-cell contacts [28] , inhibits insulin signaling [29] , and is implicated in cell transformation [30] . It is regulated by SRC3 and decreased SRC expression and kinase activity correlate with UC tumor aggressiveness [31] . rs1520896 is located on chromosome 11 but has no known gene association. However, this locus has been associated with cisplatin susceptibility in a study of lymphoblastoid cell lines [16] . Further investigation of the possible interaction between platinum and these loci is merited, including fine mapping or sequencing of these regions to identify specific causal variants, pathway analysis to identify other related genes involved, or in vitro functional studies exploring gene and protein expression in association with platinum response.
The clinical utility of the SNP score identified in this study may be improved by expansion of the exploration through a genome wide association study (GWAS). This study is biased by the a priori assumption of loci importance upon which it is based, as associations can only be made with SNPs included in the discovery panel. An agnostic GWAS of platinum response would circumvent this bias and its greater power may identify additional loci of potentially greater clinical relevance. Furthermore, it is possible that the loci identified in this study are in linkage disequilibrium with more biologically and clinically relevant loci. Fine mapping of the region surrounding significant associations identified in a GWAS may reveal a more clinically significant predictive signature. A UC GWAS for platinum sensitivity could therefore be used both to validate the findings of this study and to identify additional loci.
Validation is an essential step in the assessment of any novel biomarker. In this study, we sought to validate the association between the SNP score and platinum sensitivity in eight UC cell lines because germline DNA from an independent cohort of platinum-treated patients and their response to therapy could not be identified. A statistically significant correlation between SNP score and cisplatin sensitivity observed in the cell lines was not reached; however, the small sample size may have compromised our ability to achieve statistical significance. Our results support the need for external validation in a large set of matched somatic and germline DNA from a patient cohort and ongoing clinical trials should eventually provide this opportunity.
These germline variants predictive of UC response to platinum may be relevant in other platinum-sensitive diseases. Germline variation was recently shown to predict survival of non-small-cell lung cancer (NSCLC) after platinum-based treatment [32] . While there is an association between platinum response and survival in both NSCLC and UC, markers predictive chemotherapy response may not be prognostic for survival due to other influences, such as second-or third-line therapy. The present study had an insufficient number of events to investigate for an association with survival. However, validation of the predictive potential of this SNP signature in another platinum-sensitive malignancy would be worthwhile and a study in NSLC is planned at our center.
Once the analytic and clinical validity of a genomic test is appropriately tested, it is necessary to evaluate its clinical utility. There is debate, however, about whether prospective evaluation of the test is required before incorporating it into clinical practice. In 2004, an expert panel (Evaluation of Genomic Applications in Practice and Prevention) was established to provide evidence-based evaluations and recommendations on genetic and genomic testing [33] . It was proposed that novel tests be subjected to prospective randomized evaluation, and where possible, be compared with a current clinical standard, to compensate for unavoidable biases in a retrospectively ascertained clinical dataset such as that used in this study. A premise of this process is that it is important to determine the clinical utility of a test and demonstrate a clinical impact before widespread dissemination. This approach demands a rigorous evaluation that was not completed, for example, with the Oncotype Dx test for breast cancer. The feasibility of this approach is currently untested, but a signature for platinum sensitivity/toxic effect would appear a worthy pilot for such an approach.
In summary, this study provides a clinical example of how germline variation may have value beyond the provision of molecular insights into carcinogenesis [34, 35] and may represent a stable, pharmacogenomic biomarker amenable to high-throughput analysis. While germline variation may indicate a genomic location for deeper molecular interrogation, the question of whether a SNP signature containing loci can predict clinical end points of interest is worthy of further investigation. Moreover, a combination of somatic and germline variation may facilitate early selection of appropriate clinical trial candidates based on the molecular profile of the individual and the tumor. If sufficiently robust and validated, such an approach may ultimately direct clinical practice by selecting patients most likely to benefit from chemotherapy. disclosure DJG has received research funding from Roche. DFB has acted as a consultant for Bristol Myers Squibb and Novartis, has received honoraria from Eli-Lilly, and research funding from Novartis, Genentech, and Genta. The remaining authors have declared no conflicts of interest.
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